tesofensine

Small moleculeexperimental

Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014. — Wikipedia

Clinical trial activity

14 trials · 7 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2000 (NCT00006077)

Timeline

2000s

Jan 1, 2000
Earliest Phase 2 Sponsor(trial)
Jan 1, 2007
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Monoamine transporterINHIBITOR
Monoamine transporter inhibitor
Unspecified targetUnclear
unclear

Chemistry & pharmacology

Loading structure…

SMILES

CCOC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C

Mol. weight: 328.28 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

ns2330
tesofensine
tesofensine
tesofensine

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05198362	Phase 2	Dec 28, 2021	Saniona
NCT05147415	Phase 2	Nov 11, 2021	Saniona
NCT03845075	Phase 2	Feb 20, 2019	Saniona, University of Copenhagen
NCT03488719	Phase 1	Jul 10, 2018	Saniona
NCT03286829	Phase 1	Dec 18, 2017	Saniona
NCT03149445	Phase 2	Mar 30, 2017	Saniona
NCT02737891	Phase 2	Apr 1, 2016	Profil GmbH, Saniona
NCT00481104	Phase 2	May 1, 2007	NeuroSearch A/S, University of Copenhagen
NCT00428415	Phase 1/Phase 2 (Phase 2)	Mar 1, 2007	NeuroSearch A/S, Royal Veterinary & Agricultural University, Denmark
NCT00394667	Phase 2	Sep 1, 2006	NeuroSearch A/S, Royal Veterinary & Agricultural University, Denmark
NCT00148486	Phase 2	Jun 1, 2003	Boehringer Ingelheim
NCT00148512	Phase 2	Mar 1, 2003	Boehringer Ingelheim
NCT00153010	Phase 2	Feb 1, 2003	Boehringer Ingelheim
NCT00006077	Phase 2	Aug 1, 2000	National Institute of Neurological Disorders and Stroke (NINDS)

Showing 14 of 14 trials

Page 1 / 1

Organizations

Research & Development (7)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Saniona	For profit	7	7	2	2016
Boehringer Ingelheim	For profit	3	3	1	2003
NeuroSearch A/S	For profit	3	3	1	2006
Royal Veterinary & Agricultural University, Denmark	Academic/Hospital	2	0	1	2006
University of Copenhagen	Academic/Hospital	2	0	1	2007
National Institute of Neurological Disorders and Stroke (NINDS)	Government	1	1	1	2000
Profil GmbH	For profit	1	0	1	2016

7 organizations

Page 1 / 1